Structure-activity relationship study on small peptidic GPR54 agonists.
Tomita. Kenji K; Niida. Ayumu A; Oishi. Shinya S; Ohno. Hiroaki H; Cluzeau. Jérôme J; Navenot. Jean-Marc JM; Wang. Zi-xuan ZX; Peiper. Stephen C SC; Fujii. Nobutaka N
Key Findings
- Kisspeptin-10 (the last 10 amino acids of the natural hormone) can be shortened to a pentapeptide and still keep activity.
- A specific modified pentapeptide (H-Amb-Nal(2)-Gly-Leu-Arg-Trp-NH2) showed the strongest GPR54 agonist activity reported so far.
- The study maps which parts of the peptide are important for receptor activation, guiding future design of more potent analogues.
Practical Outcomes
- For now, the finding is mainly of scientific interest; it doesn’t translate into a usable supplement or protocol for biohackers. It suggests that more potent kisspeptin‑based compounds could be developed, but further research on safety, dosing, and real‑world effects is needed before any practical application.
Summary
Scientists tweaked the short kisspeptin-10 peptide and found a new version (called H-Amb-Nal(2)-Gly-Leu-Arg-Trp-NH2) that works even better at activating the GPR54 receptor, which is involved in hormone release. This is still early‑stage lab work and doesn’t give any dosing or safety info for people.
Abstract
Metastin (kisspeptin-54) is an endogenous ligand that modulates gonadotropin-releasing hormone (GnRH) secretion through the interaction with a G protein-coupled receptor (GPCR), GPR54. The short-chain C-terminal decapeptide amide, metastin (45-54) (kisspeptin-10), exerts the identical bioactivities to metastin, such as metastasis suppression of cancer cells and inhibition of trophoblast migration and invasion. In order to understand the structural requirement for GPR54 agonistic activity, structure-activity relationship (SAR) study on pentapeptide-based C-terminal metastin analogues was carried out. As a result, H-Amb-Nal(2)-Gly-Leu-Arg-Trp-NH2 34 was identified as a novel GPR54 agonist that possessed the most potent GPR54 agonistic activity reported so far.
Study Information
pubmed
2006
2006-08-01T00:00:00.000Z
10.1016/j.bmc.2006.07.009